Clinical Trial: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Sponsor and Collaborators
Singapore General Hospital
Contact
Contact: Daryl Tan, MBBS MRCP
65-63266604
[email protected]
Contact: Pei Woon ZN Eng, Bsc (hons)
65-63214627
[email protected]
Principal Investigator
Daryl Tan, MBBS MRCP Singapore General Hospital
ClinicalTrials.gov Identifier
NCT00901147
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.